

Pharmaceutical Benefits Scheme (PBS) Listings

1 April 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 April 2026**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Chronic treatment of hereditary angioedema Types 1 or 2

Garadacimab (200 mg/1.2 mL injection, 1.2 mL pen device) (Andembry®) is now listed on the PBS for the chronic treatment of hereditary angioedema Types 1 or 2. Authority applications for initial and grandfather treatments can be made using the Online PBS Authorities system or in writing. Authority applications to change treatment can be made using the Online PBS Authorities system or in writing. Authority applications for continuing treatment can be made using the Online PBS Authorities system or by telephone.

Chronic treatment of Acute Hepatic Porphyria (AHP)

Givosiran (189 mg/mL injection, 1 mL vial) (Givlaari®) is now listed on the PBS for the chronic treatment of AHP. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or in writing.

Cutaneous T-cell lymphoma

Mogamulizumab (20 mg/5 mL injection, 5 mL vial) (POTELIGEO®) is now listed on the PBS for the treatment of cutaneous T-cell lymphoma. Authority applications for initial treatment can be made using the Online PBS Authorities system or in writing. Authority applications for continuing treatment can be made using the Online PBS Authorities system or by telephone.

Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Repotrectinib (40 mg capsule, 120; 160 mg capsule, 60) (Augtyro®) is now listed on the PBS for the treatment of stage IIIB (locally advanced) or stage IV (metastatic) NSCLC. Authority applications for initial treatment can be made using the Online PBS Authorities system or in writing. Authority applications for continuing treatment can be made using the Online PBS Authorities system or by telephone.

Spinal muscular atrophy (SMA)

Risdiplam (5 mg tablet, 28) (Evrysdi®) has a new form listed on the PBS for the treatment of SMA. Authority applications for initial treatment can be made using the Online PBS Authorities system or in writing. Authority applications for continuing or change of treatment can be made using the Online PBS Authorities system or by telephone.

Generalised myasthenia gravis (gMG)

Zilucoplan (16.6 mg/0.416 mL injection, 28 x 0.416 mL syringes; 23 mg/0.574 mL injection, 28 x 0.574 mL syringes; 32.4 mg/0.81 mL injection, 28 x 0.81 mL syringes) (Zilbrysq®) is now listed on the PBS for the treatment of gMG. Authority applications for the treatment of acute severe gMG, bridging therapy, and for initial, continuing and grandfather treatments of treatment refractory gMG can be made using the Online PBS Authorities system or in writing.

Amyotrophic lateral sclerosis

Edaravone (30 mg/20 mL injection, 10 x 20 mL ampoules) (Radicava®) has had an amendment to the listing for the treatment of amyotrophic lateral sclerosis. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

Relapsed or refractory multiple myeloma

Elranatamab (44 mg/1.1 mL injection, 1.1 mL vial; 76 mg/1.9 mL injection, 1.9 mL vial) (Elrexfio®) is now listed on the PBS for the treatment of relapsed or refractory multiple myeloma. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

High risk and intermediate-2 risk myelofibrosis; intermediate-1 risk myelofibrosis

Fedratinib (100 mg capsule, 120) (Inrebic®) is now listed on the PBS for the treatment of high risk and intermediate-2 risk myelofibrosis and intermediate-1 risk myelofibrosis. Authority applications for initial treatment can be made using the Online PBS Authorities system or by telephone. Prescriptions for continuing treatment are Authority Required (STREAMLINED).

Cranial diabetes insipidus; primary nocturnal enuresis

Desmopressin (desmopressin acetate 10 microgram/actuation nasal spray, 50 actuations) (Desmomed®) (120 microgram sublingual tablet, 30; 240 microgram sublingual tablet, 30) (Desmopressin ADVZ®) is now listed on the PBS for the treatment of cranial diabetes insipidus and primary nocturnal enuresis. Prescriptions for treatments are Authority Required (STREAMLINED).

Urothelial Carcinoma

Durvalumab (120 mg/2.4 mL injection, 2.4 mL vial; 500 mg/10 mL injection, 10 mL vial) (Imfinzi®) is now listed on the PBS for the treatment of urothelial carcinoma. Prescriptions for initial and continuing treatments are Authority Required (STREAMLINED).

Limited-stage small cell lung cancer

Durvalumab (120 mg/2.4 mL injection, 2.4 mL vial; 500 mg/10 mL injection, 10 mL vial) (Imfinzi®) is now listed on the PBS for the treatment of limited-stage small cell lung cancer. Prescriptions for treatment are Authority Required (STREAMLINED).

Chronic heart failure

Eplerenone (25 mg tablet, 30; 50 mg tablet, 30) (APO-Eplerenone®, ESPLER®, Inpler®, Inspra®) has had a change to the restriction for the treatment of chronic heart failure. Prescriptions for treatment are Authority Required (STREAMLINED).

Moderate to severe spasticity of the upper limb; dynamic equinus foot deformity

IncobotulinumtoxinA (100 units injection, 1 vial) (Xeomin®) is now listed on the PBS for the treatment of moderate to severe spasticity of the upper limb and dynamic equinus foot deformity. Prescriptions for treatments are Authority Required (STREAMLINED).

High risk locally advanced carcinoma of the cervix

Pembrolizumab (100 mg/4 mL injection, 4 mL vial) (Keytruda®) is now listed on the PBS for the treatment of high risk locally advanced carcinoma of the cervix. Prescriptions for initial and continuing treatments are Authority Required (STREAMLINED).

Resectable locally advanced squamous cell carcinoma of the oral cavity, pharynx or larynx

Pembrolizumab (100 mg/4 mL injection, 4 mL vial) (Keytruda®) is now listed on the PBS for the treatment of resectable locally advanced squamous cell carcinoma of the oral cavity, pharynx or larynx. Prescriptions for treatment are Authority Required (STREAMLINED).

Intermediate or high risk of recurrence of clear cell variant renal cell carcinoma (RCC)

Pembrolizumab (100 mg/4 mL injection, 4 mL vial) (Keytruda®) is now listed on the PBS for the treatment of intermediate or high risk of recurrence of clear cell variant RCC. Prescriptions for treatment are Authority Required (STREAMLINED).

Constipation

MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE (macrogol-3350 13.125 g + sodium chloride 350.7 mg + sodium bicarbonate 178.5 mg + potassium chloride 46.6 mg powder for oral liquid, 30 sachets) for the treatment of constipation and faecal impaction has had a change in authority level from Restricted Benefit to Authority Required (STREAMLINED).

Note: Prescriptions written prior to 1 April 2026 can continue to be dispensed as a Restricted Benefit. Prescriptions written on or after 1 April 2026 must be authority prescriptions endorsed with the streamlined authority code.

Additions to PBS listings for 60-day prescriptions

The following medicine is now available for 60-day prescriptions on the PBS:

Semaglutide (0.68 mg/mL injection, 1 x 3 mL pen device; 1.34 mg/mL injection, 1 x 3 mL pen device) (Ozempic®) is now available for 60-day prescriptions on the PBS for the treatment of diabetes mellitus type 2. Authority applications for initial treatment can be made using the Online PBS Authorities system or by telephone. Prescriptions for continuing treatment are Authority required (STREAMLINED).

1 April 2026 delisted PBS listings

Neuromyelitis optica spectrum disorder (NMOSD)

Ravulizumab (1.1 g/11 mL injection, 11 mL vial; 300 mg/3 mL injection, 3 mL vial) (Ultomiris®) no longer has a listing for Grandfather arrangements.

Paediatric high grade glioma; paediatric low grade glioma

Dabrafenib (10 mg dispersible tablet, 2 x 210; 50 mg capsule, 120; 75 mg capsule, 120) (Tafinlar®) no longer has a listing for Grandfather arrangements.

Asthma

Beclometasone dipropionate (50 microgram/actuation inhalation, 200 actuations) (Qvar 50 Autohaler®) has been delisted with a supply only arrangement for 6 months.

Pain and inflammation

Diclofenac sodium (100 mg suppository, 20) (Voltaren 100®) has been delisted.

Nausea and vomiting

Granisetron (3 mg/3 mL injection, 3 mL ampoule) (Kytril®) has been delisted.

Severe pain

Oxycodone (30 mg suppository, 12) (Proladone®) has been delisted with a supply only arrangement for 3 months.

Pathological hyperprolactinaemia

Quinagolide (75 microgram tablet, 30) (Norprolac®) has been delisted.

IMPORTANT INFORMATION



New Adult Crohn's Disease Activity Index Form Now Available

An Adult Crohn's Disease Activity Index (CAI) Form is now available on the Services Australia website. This is a standalone CAI calculation sheet that can be used when requesting an authority via the Online PBS Authorities system.



Integrated clinical and prescribing software

Several clinical and prescribing software developers now have products available for use to request PBS authority approval directly from your clinical and prescribing software. This means you can request PBS authority approval as part of generating the authority prescription rather than calling, applying in writing or self-serving through the PBS Authorities tile in HPOS. For more information, speak with your software provider.



Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit servicesaustralia.gov.au/HPOS for more information on how to Link your Health Identifiers to HPOS and Manage delegations.



PBS Authorities items criteria

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by the PBAC, you can contact the Department of Health, Disability and Ageing by email at pbs@health.gov.au.

REMINDERS



PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.



Correct PBS item code

When requesting PBS authorities via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.



Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.



For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.